Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

91
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
91
Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

112
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

Investigational new drugs·2025
Same author

Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

JCO precision oncology·2025
Same author

Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.

The Prostate·2025
Same author

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

The New-Meaning Objection: A Reply to Nicolò D'Agruma.

Cognitive science·2025
Same author

Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer·2024

Related Experiment Video

Updated: Jun 28, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K

Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment

Paul Viscuse1, Michael Devitt1, Robert Dreicer2

  • 1Division of Hematology/Oncology, Department of Medicine, and Department of Urology, University of Virginia, Charlottesville, Virginia.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|April 11, 2024
PubMed
Summary

Radiopharmaceutical therapy, like 177Lu-PSMA-617, offers a new non-androgen-directed treatment for metastatic prostate cancer, improving survival. Research explores combining it with other therapies for better patient outcomes.

Keywords:
PSMAlutetiummetastatic prostate cancertheranostics

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Experiment Videos

Last Updated: Jun 28, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Area of Science:

  • Oncology
  • Nuclear Medicine

Background:

  • Metastatic prostate cancer is heterogeneous with variable resistance to current therapies, remaining a leading cause of cancer death.
  • Androgen receptor-directed therapy (with or without taxanes) is the standard backbone treatment.
  • Radiopharmaceutical therapy presents a novel, non-androgen-directed approach for metastatic castration-resistant prostate cancer.

Purpose of the Study:

  • To review the current metastatic prostate cancer treatment landscape, focusing on radiopharmaceutical therapy.
  • To discuss 177Lu-PSMA-617, its clinical challenges, and potential combination strategies.
  • To introduce emerging radiopharmaceutical therapies for metastatic prostate cancer.

Main Methods:

  • Review of current literature on metastatic prostate cancer treatment.
  • Focus on radiopharmaceutical therapy, specifically 177Lu-PSMA-617.
  • Exploration of clinical challenges and future investigative efforts.

Main Results:

  • 177Lu-PSMA-617 demonstrates impact on patient survival in metastatic castration-resistant prostate cancer.
  • Clinical challenges exist with 177Lu-PSMA-617, prompting research into combination regimens and earlier use.
  • Alternative radiopharmaceutical therapies are under investigation for improved treatment algorithms.

Conclusions:

  • Radiopharmaceutical therapy, exemplified by 177Lu-PSMA-617, is a promising personalized treatment modality for metastatic prostate cancer.
  • Optimizing the use of radiopharmaceuticals through combination therapies or earlier administration may further enhance patient outcomes.
  • Ongoing research into novel radiopharmaceutical agents holds potential for future integration into prostate cancer treatment strategies.